Companies: 10,795·Total market cap: $144.5T
Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTXNASDAQHealthcare
$9.50
+$0.00(+0.00%)
Market Cap$925933688
P/E Ratio—
52W High$9.67
52W Low$1.87
SEC Filings

Poseida Therapeutics, Inc. (PSTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001661460 · PSTX · NASDAQ · as of Jun 8, 2026

Filing snapshot

335
Total Filings
SCHEDULE 13G/A
Latest Form
2025-05-15
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001661460 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-03-07
Fiscal Year End
Mar 7, 2024
Accession No.
0000950170-24-027998
Primary Document
pstx-20231231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001661460 · Accession 0000950170-24-027998

Latest Key Filings

10-QQuarterly Report
10-Q
2024-11-07
View 10-Q on SEC
8-KCurrent Report
8-K
2025-01-08Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-02-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-07
View
15-12G15-12G
15-12G
2025-01-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-01-15
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-01-13
View
EFFECTEFFECT
EFFECT
2025-01-10
View
EFFECTEFFECT
EFFECT
2025-01-10
View
S-8 POSS-8 POS
S-8 POS
2025-01-08
View
S-8 POSS-8 POS
S-8 POS
2025-01-08
View
S-8 POSS-8 POS
S-8 POS
2025-01-08
View
S-8 POSS-8 POS
S-8 POS
2025-01-08
View
S-8 POSS-8 POS
S-8 POS
2025-01-08
View
POS AMPOS AM
POS AM
2025-01-08
View
Showing 1–15 of 213 filingsForm 4 / 144 hidden· 335 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001661460  |  Exchange: NASDAQ · Healthcare

Poseida Therapeutics, Inc. (NASDAQ: PSTX) has submitted 335 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001661460, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Poseida Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Poseida Therapeutics, Inc. 10-K was filed on 2024-03-07 for fiscal year ending 2024. Historical PSTX 10-K annual reports are available from 2015 through 2024.

Investors researching Poseida Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
VECT SEC Filings →VERV SEC Filings →ALBO SEC Filings →HARP SEC Filings →CMRX SEC Filings →CDMO SEC Filings →ICPT SEC Filings →ICVX SEC Filings →
→ PSTX Financials→ PSTX Earnings→ PSTX Insider Trades

Frequently Asked Questions

PSTX SEC Filings · 8 questions

Poseida Therapeutics, Inc. (PSTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 335 filings and access original documents at no cost. Poseida Therapeutics, Inc.'s CIK is 0001661460.

PSTX SEC filingsPoseida Therapeutics, Inc. SEC documentsfind PSTX 10-K